NCT03662191View on ClinicalTrials.gov

Phase I Safety, Pharmacokinetics and Bioavailability Study Comparing Rate and Extent of Absorption of Two Different Forms of Tafamidis (PF-6291826)

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 28, 2018

Primary Completion Date

January 10, 2019

Study Completion Date

January 10, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

Tafamidis

bioavailability study

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03662191 - Phase I Safety, Pharmacokinetics and Bioavailability Study Comparing Rate and Extent of Absorption of Two Different Forms of Tafamidis (PF-6291826) | Biotech Hunter | Biotech Hunter